GURUFOCUS.COM » STOCK LIST » Healthcare » Drug Manufacturers » Gilead Sciences Inc (MIL:1GILD) » Definitions » Debt-to-Revenue

Gilead Sciences (MIL:1GILD) Debt-to-Revenue : 0.88 (As of Dec. 2023)


View and export this data going back to 2017. Start your Free Trial

What is Gilead Sciences Debt-to-Revenue?

Debt-to-Revenue measures a company's ability to pay off its debt.

Gilead Sciences's Short-Term Debt & Capital Lease Obligation for the quarter that ended in Dec. 2023 was €1,649 Mil. Gilead Sciences's Long-Term Debt & Capital Lease Obligation for the quarter that ended in Dec. 2023 was €21,264 Mil. Gilead Sciences's annualized Revenue for the quarter that ended in Dec. 2023 was €26,094 Mil. Gilead Sciences's annualized Debt-to-Revenue for the quarter that ended in Dec. 2023 was 0.88.


Gilead Sciences Debt-to-Revenue Historical Data

The historical data trend for Gilead Sciences's Debt-to-Revenue can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Gilead Sciences Debt-to-Revenue Chart

Gilead Sciences Annual Data
Trend Dec14 Dec15 Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23
Debt-to-Revenue
Get a 7-Day Free Trial Premium Member Only Premium Member Only 1.10 1.27 0.98 0.93 0.92

Gilead Sciences Quarterly Data
Mar19 Jun19 Sep19 Dec19 Mar20 Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23
Debt-to-Revenue Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 0.85 0.99 0.96 0.89 0.88

Competitive Comparison of Gilead Sciences's Debt-to-Revenue

For the Drug Manufacturers - General subindustry, Gilead Sciences's Debt-to-Revenue, along with its competitors' market caps and Debt-to-Revenue data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Gilead Sciences's Debt-to-Revenue Distribution in the Drug Manufacturers Industry

For the Drug Manufacturers industry and Healthcare sector, Gilead Sciences's Debt-to-Revenue distribution charts can be found below:

* The bar in red indicates where Gilead Sciences's Debt-to-Revenue falls into.



Gilead Sciences Debt-to-Revenue Calculation

Debt-to-Revenue measures a company's ability to pay off its debt.

Gilead Sciences's Debt-to-Revenue for the fiscal year that ended in Dec. 2023 is calculated as

Debt-to-Revenue=Total Debt / Revenue
=(Short-Term Debt & Capital Lease Obligation + Long-Term Debt & Capital Lease Obligation) / Revenue
=(1648.766 + 21264.313) / 24865.372
=0.92

Gilead Sciences's annualized Debt-to-Revenue for the quarter that ended in Dec. 2023 is calculated as

Debt-to-Revenue=Total Debt / Revenue
=(Short-Term Debt & Capital Lease Obligation + Long-Term Debt & Capital Lease Obligation) / Revenue
=(1648.766 + 21264.313) / 26094.152
=0.88

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

In the calculation of annual Debt-to-Revenue, the Revenue of the last fiscal year is used. In calculating the annualized quarterly data, the Revenue data used here is four times the quarterly (Dec. 2023) Revenue data.


Gilead Sciences Debt-to-Revenue Related Terms

Thank you for viewing the detailed overview of Gilead Sciences's Debt-to-Revenue provided by GuruFocus.com. Please click on the following links to see related term pages.


Gilead Sciences (MIL:1GILD) Business Description

Address
333 Lakeside Drive, Foster, CA, USA, 94404
Gilead Sciences develops and markets therapies to treat life-threatening infectious diseases, with the core of its portfolio focused on HIV and hepatitis B and C. The acquisitions of Corus Pharma, Myogen, CV Therapeutics, Arresto Biosciences, and Calistoga have broadened this focus to include pulmonary and cardiovascular diseases and cancer. Gilead's acquisition of Pharmasset brought rights to hepatitis C drug Sovaldi, which is also part of combination drug Harvoni, and the Kite, Forty Seven, and Immunomedics acquisitions boost Gilead's exposure to cell therapy and noncell therapy in oncology.

Gilead Sciences (MIL:1GILD) Headlines

No Headlines